Kornimate/medical-research-clean huggingface dataset:
use of lumella-glycosylated fibronectin for diagnosis of preeclampsia

Conditions: Preeclampsia; Pregnancy Related; Hypertension

Summary: women with symptoms of preeclampsia from antenatal clinic or triage will be offered lumella test along with traditional blood tests. if lumella test is positive which will be compared with the traditional blood test results. once 50 positive cases have been analysed the study results will be submitted to nice.

pre-eclampsia is a potentially serious condition that affects pregnant women. it is usually diagnosed during routine antenatal appointments. this is based on blood pressure measurements and results of urine protein tests that are recommended at each routine antenatal visit to screen for the condition. the triage plgf test and the elecsys immunoassay sflt-1/plgf ratio is also recommended to help rule out the condition in women presenting with suspected pre-eclampsia between 20 weeks and 34 weeks of pregnancy plus 6 days. if diagnosed with pre-eclampsia, women are usually referred to a specialist in hospital for further tests and more frequent monitoring. depending on the severity of the condition, some women may be monitored as outpatients while others may need admission to hospital for closer monitoring or to have the condition managed in a critical care setting. the lumella test is based on the novel biomarker glyfn. the company states that compared with other currently used biomarkers (such as soluble fms-like tyrosine kinase-1 \[sfit-1\] and placental growth factor \[plgf\] or plgf alone), glyfn is etiological to pre-eclampsia and maintains a linear progression throughout pregnancy. the company also claims that the test offers improved sensitivity and specificity over standard care tests. this would lead to a reduction in false positives and false negatives. the lumella test requires a finger prick blood sample (5 microlitres). other pre-eclampsia tests currently used in the nhs need a phlebotomy blood sample, which can be difficult to collect in some people. the test can also be transported and stored at room temperature. other tests for pre-eclampsia need to be refrigerated and brought to room temperature before the test can be done. the lumella test may improve patient experience and allow a more rapid turnaround time for results. the company states that lumella is currently the only test that can be done within 10 minutes at room temperature.

Eligibility criteria:
inclusion criteria: * if they can speak english * can give informed consent * has symptoms of preeclampsia exclusion criteria: * can't speak english * does not want to participate

Keywords: preeclampsia pet
informing pain treatment using pharmacogenomic analysis

Conditions: Adult Patients Who Are Receiving Oncologic Care

Summary: this is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (pgx) testing on opioid dosing decisions/selections and pain score in cancer patients.


Eligibility criteria:
inclusion criteria: * persons receiving ongoing oncology care at the university of chicago medical center for whom near-future pain opioid pain medication therapy is anticipated * subjects must be at least 18 years of age. exclusion criteria: * subjects taking an opioid at the time of enrollment, or within the past 30 days * subjects who are currently undergoing palliative radiation * subjects who have undergone, or are being actively considered for, bone marrow, liver or kidney transplantation. * subjects with a history of or active blood cancer (e.g., leukemia). * chronic kidney disease, as defined by glomerular filtration rate (gfr) \< 30/ml/min/1.73m2, due to the risk of decreased drug excretion. * liver dysfunction, as defined by the following laboratory values, due to the risk of decreased drug metabolism: total bilirubin greater than or equal to1.5 mg/dl, aspartate aminotransferase (ast) and alanine aminotransferase (alt) greater than or equal to 2.5 x upper limit of normal\*. (\*aspartate aminotransferase (ast) and alanine aminotransferase (alt) \\ greater than or equal to 5 x upper limit of normal if hepatic metastases are present). * inability to understand and give informed consent to participate in the opinion of the investigator * subjects who are known to be pregnant at the time of enrollment * subjects who have previously or are currently enrolled in another institutional pharmacogenomic genotyping study, or are known to have previously undergone pharmacogenomic genotyping for the gene(s) of interest via another commercial or other means.

Keywords: pharmacogenomic opioids
a study of infliximab (remicade) in patients with ankylosing spondylitis.

Conditions: Ankylosing Spondylitis

Summary: a study of the safety and efficacy of infliximab (remicade) versus placebo in subjects with ankylosing spondylitis

this is a clinical research study that will determine if there is a reduction in the signs and symptoms (such as back pain and stiffness) of patients with ankylosing spondylitis with infliximab therapy. this study will also study the safety of infliximab in patients with ankylosing spondylitis. the effect of infliximab on physical function, damage to joints and the quality of life in patients with ankylosing spondylitis will also be studied. subjects received infusions of either placebo at weeks 0, 2, 6, 12, 18 and 5 mg/kg infliximab at weeks 24, 26, 30 and every 6 weeks through week 96, or 5 mg/kg infliximab at weeks 1, 2, 6, 12, 18 and every 6 weeks through week 96

Eligibility criteria:
inclusion criteria: * have had a diagnosis of definite akylosing spondylitis for at least 3 months prior to screening * have active disease with spinal pain * receiving or intolerant to standard anti-inflammatory agents exclusion criteria: * have rheumatoid arthritis, systemic lupus erythematosus, or other inflammatory rheumatic disease * have a documented history of fibromyalgia * have total ankylosis

Keywords: ankylosing spondylitis infusion
health literacy project

Conditions: Epilepsy

Summary: evaluating changes in knowledge, attitude, and practices (kap) related to epilepsy and its treatment as a result of an educational intervention among adolescents with epilepsy to determine if improved kap about epilepsy results in improved medication adherence and less perceived stigma.

this proof-of-concept study aims to evaluate the impact of a targeted health literacy intervention on knowledge and attitudes about epilepsy and its treatment, and reported medication adherence and stigma among adolescents with epilepsy in uganda. research questions: 1. what is the impact of a culturally relevant information session on the knowledge of epilepsy and its treatment among adolescents with epilepsy in uganda? 2. what is the impact of such an educational session on reported medication adherence and reported stigma among this group? the investigators hypothesize that a culturally relevant educational intervention will significantly improve knowledge about epilepsy and its treatment, increase medication adherence, and reduce stigma among adolescents with epilepsy in uganda. this hypothesis is based on the premise that tailored health literacy interventions can address specific misconceptions and barriers to care, thereby improving health outcomes for pwe (persons with epilepsy) in contexts burdened by significant treatment gaps and cultural stigmatization.

Eligibility criteria:
inclusion criteria: * adolescents with a diagnosis of epilepsy attending a clinic at one of the study sites. * ages 12-18 years * ability and willingness to provide informed assent and guardian consent to participate in the study. * english, runyankole or luganda language proficiency. exclusion criteria: * unable or unwilling to provide informed consent or assent to participate in the study. * developmental/cognitive challenges that hinder participation in the intervention or completion of surveys.
24 month follow-up of patients with osgood schlatter (osd)

Conditions: Osgood-Schlatter Disease; Apophysitis

Summary: osgood schlatter is a common knee condition, affecting approximately 10% of adolescents. osd is thought to be a growth related pain conditon, and thus resolve after maturation. despite this, there a lack of prospective data investigating whether this is in fact the case.

this is a prospective cohort study of 51 adolescents (aged 10-14 at baseline) with osgood schlatter. participants are followed for two years.

Eligibility criteria:
inclusion criteria: * 10-14 years of age * pain at tibial tuberosity during two or more of the following activities: sitting with a bent knee, squatting, running, jumping or stair ambulation * pain during palpation of tibial tuberosity * knee pain for 6 weeks or more exclusion criteria: * other knee conditions that may manifest as anterior knee pain (patellofemoral pain, iliotibial band syndrome, sinding-larson-johanson disease). * previous surgery * pain from the hip or back that interferes with activities of daily living. * habitual patella luxations * clinical suspicion of meniscal lesion
trans-arterial chemoembolization in patients with hepatocellular carcinoma: a study of different outcomes and their predictive factors

Conditions: Liver Cancer

Summary: radiological response after trans arterial chemoembolization (tace) is classified according to modified response evaluation criteria in solid tumors (mrecist) to: complete response (cr) (disappearance of arterial enhancement), partial response (pr) ( at least a 30% decrease in the sum of diameters of viable enhancement), progressive disease (pd) (an increase of at least 20% in the sum of the diameters of viable enhancement, or appearance of new lesions), and stable disease (any cases that do not qualify for either partial response or progressive disease

post-tace response of treatment for cases of hepatocellular cancer

Eligibility criteria:
inclusion criteria: clinical history and examination with special stress on symptoms and signs of chronic liver disease with or without evidence of hepatic decompensation e.g. the presence of ascites and with or without evidence of complications e.g. jaundice spider naevi, bleeding varices, ascites, and lower limb edema. laboratory findings in the form of raised bilirubin and liver enzymes, impaired coagulation profile, and/or low serum albumin. abdominal ultrasonography revealing liver cirrhosis (coarse echopattern, attenuated hepatic veins, irregular outlines, hypertrophy of caudate lobe and/or shrunken liver, presence of focal hepatic) and presence of splenomegaly, ascites, or portal vein thrombosis (pvt). exclusion criteria: a patient who had surgical resection or liver transplantation patients refuse to participate hepatic focal lesion other than hcc
interactions between cranberry juice and antibiotics used to treat urinary tract infections

Conditions: Urinary Tract Infections

Summary: the purpose of study is to determine whether cranberry juice interacts with antibiotics used to treat urinary tract infections (utis).

although evidence of its effectiveness is limited, cranberry juice is widely used to prevent urinary tract infections (utis). however, recent studies have shown that cranberry juice may affect the way the body absorbs and metabolizes antibiotics used to treat utis. this study will determine whether concurrent cranberry juice administration lowers the urinary concentrations of two commonly used antibiotics, amoxicillin and cefaclor. this study will involve children being treated for utis and adults without utis. all of the children will continue their prescribed amoxicillin/cefaclor treatment. after 7 to 10 days of antibiotic treatment, the children will be assigned to receive either cranberry juice for 2 days or no additional treatment. urine samples will be collected from all child participants before and after the administration of cranberry juice to examine the excretion of the antibiotics. adult participants will receive two different doses of amoxicillin, with or without cranberry juice. blood and urine samples will be collected to evaluate the effect of cranberry juice on the absorption and elimination of amoxicillin.

Eligibility criteria:
inclusion criteria for children: * urinary tract infection (uti) treated with cefaclor or amoxicillin inclusion criteria for adults: * no uti exclusion criteria: * allergies to antibiotics * use of medications other than oral contraceptives * pregnancy or breast-feeding * smoker

Keywords: vaccinium macrocarpon
efficacy and safety of liraglutide in subjects with type 1 diabetes undergoing islet cell transplantation

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial is conducted in europe and north america. the aim of this trial is to investigate if liraglutide treatment can increase the proportion of insulin-independent subjects one year after islet cell transplantation who required only one (single-donor) islet cell transplant.


Eligibility criteria:
inclusion criteria: * type 1 diabetes mellitus for at least 5 years * candidate for islet cell transplantation based upon local accepted practice and guidelines * reduced awareness of hypoglycaemia exclusion criteria: * treatment with any anti-diabetic medication other than insulin including insulin pump within 4 weeks of trial start * any previous organ transplantation * a history of acute idiopathic or chronic pancreatitis * family or personal history of multiple endocrine neoplasia type 2 (men2) or familial medullary thyroid carcinoma (fmtc)
a study of rc48-adc combined with cadonilimab（ak104）in the treatment of her2-expression locally advanced or metastatic urothelial carcinoma

Conditions: Urothelial Carcinoma

Summary: this study will evaluate the efficacy and safety of rc48-adc combined with ak104 in her2-expression locally advanced or metastatic urothelial carcinoma.


Eligibility criteria:
inclusion criteria: * voluntary agreement to provide written informed consent. * male or female, age ≥ 18 years. * predicted survival ≥ 6 month. * histologically and/or cytologically confirmed locally advanced or metastatic urothelial carcinoma (including urothelial carcinoma originating in the renal pelvis, ureter, bladder, or urethra). * pior not received systemic therapy, and can not tolerant cisplatin or refuse chemotherapy. * her2 expressing (i.e. ihc 1+ 2+ or 3+) as confirmed by the local lab. * eastern cooperative oncology group (ecog) performance status score of 0 or 1. * have at least one evaluable lesion (recist 1.1 criteria) * adequate organ function, evidenced by the following laboratory results within 7 days prior to the study treatment. * male and female participants are eligible to participate if they agree to the contraception use as per study protocol. * willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol. exclusion criteria: * has received other antitumor therapy before planned start of trial treatment. * previously received allogeneic stem cell or parenchymal organ transplantation; * previously or currently suffering from congenital or acquired immunodeficiency diseases; * known or suspected to have a history of allergies to similar drugs such as rc48-adc and anti-pd-1, or has a history of hypersensitivity to chimeric or humanized antibodies or fusion proteins, or is allergic to excipients of the study drug. * diagnosed with hbsag, hbcab positive and hbv dna copy positive, or hcvab positive, or hivab positive. * has received a live virus vaccine within 4 weeks of planned start of trial treatment. * nyha class iii or iv heart failure. * suffering from active infection requiring systemic treatment. * uncontrolled hypertension, diabetes, interstitial lung disease, or copd; * required systemic treatment with glucocorticoid (\>10 mg/day of prednisone or equivalent glucocorticoid) or other immunosuppressive agents within 14 days prior to enter the trial. * history of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with a similar curative outcome as those mentioned above. * has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. * pregnancy or lactation. * assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
mood and nutrition interventions in polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome (PCOS)

Summary: the purpose of this study is to help determine the best treatment plan for women with pcos who are overweight or obese and experiencing significant symptoms of depression and anxiety. specifically, the investigators are attempting to see if there is a difference between cognitive behavioral therapy in combination with nutritional counseling in improving mood symptoms, response to stress, and risk factors for heart disease compared to nutrition counseling alone. the investigators hypothesize that combined treatment with cognitive behavioral therapy (cbt) and nutritional counseling will be more beneficial.

this study will assess the impact of treatment of mood and associated anxiety disorders in conjunction with nutritional/exercise counseling in overweight/obese women with pcos on cardiometabolic risk. the investigators hypothesize that women with pcos will have greater benefit from dual intervention (psychological and nutritional/exercise counseling) for change in depressive symptoms and cardiometabolic risk reduction compared to nutritional/exercise counseling alone. in addition, the investigators hypothesize that psychological counseling may improve cardiometabolic risk by decreasing stress responses and stress associated markers of inflammation.

Eligibility criteria:
inclusion criteria: * diagnosis of polycystic ovary syndrome (pcos) * overweight or obese (bmi 27-50) * screen positive for symptoms of depression exclusion criteria: * smoking 5 or more cigarettes per day * severe depression/anxiety warranting immediate treatment * actively participating in a weight loss program * taking medications to control cholesterol or diabetes * on hormonal therapy (must be discontinued to be eligible) * pregnancy or planning to become pregnant during the study period * inability to commute to philadelphia for weekly study sessions

Keywords: polycystic ovary syndrome pcos depression anxiety weight loss exercise nutrition therapy mood symptoms stress
the success of opening single cto lesions to improve myocardial viability study (sos-comedy)

Conditions: Hibernation, Myocardial; Complete Occlusion of Coronary Artery

Summary: the purpose of this study is to investigate the effect of percutaneous coronary intervention (pci) on myocardial viability in coronary artery disease patients with single coronary total occlusion (cto) lesions.

patients with coronary artery disease might benefit from successful percutaneous coronary intervention (pci). however, there is currently no consensus on an optimal treatment modality for single lesions resulting in coronary total occlusion (cto). since the other coronary arteries are often lesion-free, or with stenosis of less than 50%, patients often present with no symptoms. although the expert consensus on cto lesion suggests reducing the incidence of long-term adverse events via successful revascularization, there are few retrospective studies on single cto lesions. to date, it is unclear whether successful pci based on optimal medication treatment (omt) can increase myocardial viability and the extent of myocardial viability related to prognosis of those cto patients. therefore, the aim of this multi-center, prospective, open labeled, non-randomized controlled study was to determine if the improvement to myocardial viability in single cto patients with successful pci plus omt was superior to that of patients with only omt.

Eligibility criteria:
inclusion criteria: * history of stable or unstable angina * lvef \> 35% on transthoracic echocardiography measurement * single lesion occluding the coronary artery detected by angiography or mscta, with or without stenosis of other coronary arteries (≤ 50% stenotic lesion) * availability for follow-up for up to 12 months * no major barriers to provide written consent exclusion criteria: * acute q-wave myocardial infarction during the latest 3 months * revascularization in the non-culprit artery during the latest one month * unsuitable for pci * unable to tolerate dual antiplatelet treatment (dapt) * severe abnormal hematopoietic system, such as platelet count of \ 700×109/l and white blood cell count of \< 3×109/l * active bleeding or bleeding tendency * severe coexisting conditions, such as severe renal insufficiency (gfr \< 60 ml/min•1.73m2), severe hepatic dysfunction \[elevated alt (glutamic-pyruvic transaminase) or ast (glutamic-oxal acetic transaminase) level by more than three-fold of the normal limitation\], acute or chronic heart failure (nyha iii-iv), acute infectious diseases, immune disorders, malignancy, etc. * life expectancy \< 12 months * pregnancy or planning pregnancy * drug allergies or contraindications to aspirin, clopidogrel, ticagrelor, statins, contract, anticoagulant, stent, etc. * participation or planning to participate in another clinical trial during the same period * refusal to comply with the study protocol

Keywords: pet-ct cardiac magnetic resonance (cmr) imaging major adverse cardiac events (maces) coronary artery disease
spect/ct in the diagnosis of dementia

Conditions: Dementia

Summary: aim of the study is to evaluate whether tc-99m-ecd-spect/ct enhances early diagnosis of dementia in two specific patient groups: (1) patient with mild cognitive impairment, and (2) patient with possible symptoms and signs of frontotemporal dementia. evaluation of spect/ct data is performed both by visual and quantitative voxel-based analyses (statistical parametric mapping). the final diagnosis is based on up to four years clinical follow-up.


Eligibility criteria:
inclusion criteria (one of these): * healthy control * mild cognitive impairment (recruited from a population based data) * clinically suspected frontotemporal dementia (unset diagnosis) exclusion criteria: * unable to be scanned with spect/ct

Keywords: diagnosis dementia imaging
wearable sensors and molecular omics to detect and mitigate cell therapy adverse events

Conditions: Hodgkin Lymphoma; Non Hodgkin Lymphoma; Leukemia; Multiple Myeloma

Summary: the purpose of this study is to monitor physiological and molecular changes during and following car-t cancer cell therapy, towards improved management of adverse events including cytokine release syndrome and neurotoxicity. our study aims are to improved early detection and precise management of adverse events for patients receiving chimeric antigen receptor t- cell (car-t): 1. to assess the feasibility, including accuracy, usability, and usefulness of wearable sensors in car-t patients. 2. to generate comprehensive multiomic profile analysis following car-t therapy. 3. to perform integrated analysis of wearables sensor data, omics data, and symptom/clinical data.


Eligibility criteria:
inclusion criteria: * participant must be in the process of undergoing cancer cell therapy at stanford university. * adults \> 18 years * any cell target may be used. (e.g. cd19, cd22, bispecific cd19/22, bispecific cd19/20, etc.) * english speaking * assessed ability for caregiver/patient to use wearable devices and independently perform blood microsample collection exclusion criteria: * in the investigator's judgment, the subject is unlikely to comply with all protocolrequired study visits or procedures.